Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection

Human soluble ACE2 improves the effect of remdesivir in SARS‐CoV‐2 infection

Abstract There is a critical need for safe and effective drugs for COVID‐19. Only remdesivir has received authorization for COVID‐19 and has been shown to improve outcomes but not decrease mortality. However, the dose of remdesivir is limited by hepatic and kidney toxicity. ACE2 is the critical cell...

Full description

Bibliographic Details
Main Authors: Vanessa Monteil, Matheus Dyczynski, Volker M Lauschke, Hyesoo Kwon, Gerald Wirnsberger, Sonia Youhanna, Haibo Zhang, Arthur S Slutsky, Carmen Hurtado del Pozo, Moritz Horn, Nuria Montserrat, Josef M Penninger, Ali Mirazimi
Format: Article
Language:English
Published: Wiley 2021-01-01
Series:EMBO Molecular Medicine
Subjects:
clinical trial
combination therapy
COVID‐19
treatment
Online Access:https://doi.org/10.15252/emmm.202013426

Internet

https://doi.org/10.15252/emmm.202013426

Similar Items